CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70 antigen positive Relapsed/Refractory Lymphoma . In this clinical trial, at least 12 eligible patients in dose escalation period will be enrolled to receive 3 doses of CD70-CAR cell therapy according to the "3+3" principle. In dose expansion period, additional at most 21 eligible patients will be enrolled to receive CD70-CAR-T cell therapy at dose of recommended phase 2 do

Trial Details

NCT ID
NCT05948033
Phase
PHASE1 / PHASE2
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CD70-targeting CAR-T cells
Locations (sample)
  • Beijing, Biotherapeutic Department of Chinsese PLA Gereral Hospital, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients eligible for inclusion in this study had to meet all of the following criteria:
  • Age 18-75 (inclusive);
  • ECOG performance status ≤2 and Estimated life expectancy of more than 3 months;
  • Patients with histologically confirmed lymphoma including the following types defined by the World Health Organization(WHO) 2016:HL,Aggressive B-ce…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →